NitroMed BiDil
This article was originally published in Pharmaceutical Approvals Monthly
Executive Summary
The African American Heart Failure Trial (A-HeFT), the first prospective trial conducted exclusively in black men and women with heart failure, begins. The double-blind, placebo-controlled study is randomizing patients to receive BiDil (hydralazine HCl and isosorbide) or placebo in addition to their standard therapy (ACE inhibitors, digitalis, diuretics and beta-blockers). The study, initiated March 17, will enroll 600 patients with moderate to severe heart failure and a reduced ejection fraction who had at least one hospitalization for heart failure in the preceding 12 months. NitroMed submitted a BiDil NDA for treatment of heart failure in African Americans in July 200
You may also be interested in...
Executives On The Move: Changes At The Top At Enzolytics, Dyne Therapeutics And Seres Therapeutics
Recent moves in the industry include new chief financial officers at LENZ Therapeutics and Botanix Pharmaceuticals, plus new chief medical officers at Vigil Neuroscience and Voyager Therapeutics.
Israel's Gamida Cell Survives By Selling To Lender
Having finally secured US approval for Omisirge, Gamida was hoping to bag a strategic partner for the cell therapy. A year on, no suitable partner has been identified and the firm is delisting from the NASDAQ and going private.
EU Regulatory Assessors Get AI Boost In Reaching Scientific Decisions
The European Medicines Agency is training scientific staff working for the European medicines regulatory network in how to use a new AI-powered search engine that allows them to easily retrieve information on regulatory precedents.